Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation

被引：7

作者：

Morgensztern, Daniel ^{[1
]}

Govindan, Ramaswamy ^{[1
]}

机构：

[1] Washington Univ, Div Med Oncol, Dept Med, Sch Med, St Louis, MO 63110 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 12期

关键词：

CELL LUNG-CANCER; CHECKPOINT INHIBITORS; SURVIVAL;

D O I：

10.1016/j.jtho.2021.07.034

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1999 / 2001

页数：3

共 17 条

[1] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[2] Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy [J].

Aredo, Jacqueline V. ;

Mambetsariev, Isa ;

Hellyer, Jessica A. ;

Amini, Arya ;

Neal, Joel W. ;

Padda, Sukhmani K. ;

McCoach, Caroline E. ;

Riess, Jonathan W. ;

Cabebe, Elwyn C. ;

Naidoo, Jarushka ;

Abuali, Tariq ;

Salgia, Ravi ;

Loo Jr, Billy W. ;

Diehn, Maximilian ;

Han, Summer S. ;

Wakelee, Heather A. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (06) :1030-1041

[3] Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade [J].

Dovedi, Simon J. ;

Adlard, Amy L. ;

Lipowska-Bhalla, Grazyna ;

McKenna, Conor ;

Jones, Sherrie ;

Cheadle, Eleanor J. ;

Stratford, Ian J. ;

Poon, Edmund ;

Morrow, Michelle ;

Stewart, Ross ;

Jones, Hazel ;

Wilkinson, Robert W. ;

Honeychurch, Jamie ;

Illidge, Tim M. .

CANCER RESEARCH, 2014, 74 (19) :5458-5468

[4] Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines [J].

Ettinger, David S. ;

Wood, Douglas E. ;

Aisner, Dara L. ;

Akerley, Wallace ;

Bauman, Jessica R. ;

Bharat, Ankit ;

Bruno, Debora S. ;

Chang, Joe Y. ;

Chirieac, Lucian R. ;

D'Amico, Thomas A. ;

Dilling, Thomas J. ;

Dowell, Jonathan ;

Gettinger, Scott ;

Gubens, Matthew A. ;

Hegde, Aparna ;

Hennon, Mark ;

Lackner, Rudy P. ;

Lanuti, Michael ;

Leal, Ticiana A. ;

Lin, Jules ;

Loo, Billy W., Jr. ;

Lovly, Christine M. ;

Martins, Renato G. ;

Massarelli, Erminia ;

Morgensztern, Daniel ;

Ng, Thomas ;

Otterson, Gregory A. ;

Patel, Sandip P. ;

Riely, Gregory J. ;

Schild, Steven E. ;

Shapiro, Theresa A. ;

Singh, Aditi P. ;

Stevenson, James ;

Tam, Alda ;

Yanagawa, Jane ;

Yang, Stephen C. ;

Gregory, Kristina M. ;

Hughes, Miranda .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (03) :254-266

[5] Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial [J].

Faivre-Finn, Corinne ;

Vicente, David ;

Kurata, Takayasu ;

Planchard, David ;

Paz-Ares, Luis ;

Vansteenkiste, Johan F. ;

Spigel, David R. ;

Garassino, Marina C. ;

Reck, Martin ;

Senan, Suresh ;

Naidoo, Jarushka ;

Rimner, Andreas ;

Wu, Yi-Long ;

Gray, Jhanelle E. ;

Ozguroglu, Mustafa ;

Lee, Ki H. ;

Cho, Byoung C. ;

Kato, Terufumi ;

de Wit, Maike ;

Newton, Michael ;

Wang, Lu ;

Thiyagarajah, Piruntha ;

Antonia, Scott J. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (05) :860-867

[6] EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis [J].

Gainor, Justin F. ;

Shaw, Alice T. ;

Sequist, Lecia V. ;

Fu, Xiujun ;

Azzoli, Christopher G. ;

Piotrowska, Zofia ;

Huynh, Tiffany G. ;

Zhao, Ling ;

Fulton, Linnea ;

Schultz, Katherine R. ;

Howe, Emily ;

Farago, Anna F. ;

Sullivan, Ryan J. ;

Stone, James R. ;

Digumarthy, Subba ;

Moran, Teresa ;

Hata, Aaron N. ;

Yagi, Yukako ;

Yeap, Beow Y. ;

Engelman, Jeffrey A. ;

Mino-Kenudson, Mari .

CLINICAL CANCER RESEARCH, 2016, 22 (18) :4585-4593

[7] Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors [J].

Galluzzi, Lorenzo ;

Humeau, Juliette ;

Buque, Aitziber ;

Zitvogel, Laurence ;

Kroemer, Guido .

NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (12) :725-741

[8] Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study [J].

Garassino, Marina Chiara ;

Cho, Byoung-Chul ;

Kim, Joo-Hang ;

Mazieres, Julien ;

Vansteenkiste, Johan ;

Lena, Herve ;

Jaime, Jesus Corral ;

Gray, Jhanelle E. ;

Powderly, John ;

Chouaid, Christos ;

Bidoli, Paolo ;

Wheatley-Price, Paul ;

Park, Keunchil ;

Soo, Ross A. ;

Huang, Yifan ;

Wadsworth, Catherine ;

Dennis, Phillip A. ;

Rizvi, Naiyer A. .

LANCET ONCOLOGY, 2018, 19 (04) :521-536

[9] EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer [J].

Hastings, K. ;

Yu, H. A. ;

Wei, W. ;

Sanchez-Vega, F. ;

DeVeaux, M. ;

Choi, J. ;

Rizvi, H. ;

Lisberg, A. ;

Truini, A. ;

Lydon, C. A. ;

Liu, Z. ;

Henick, B. S. ;

Wurtz, A. ;

Cai, G. ;

Plodkowski, A. J. ;

Long, N. M. ;

Halpenny, D. F. ;

Killam, J. ;

Oliva, I ;

Schultz, N. ;

Riely, G. J. ;

Arcila, M. E. ;

Ladanyi, M. ;

Zelterman, D. ;

Herbst, R. S. ;

Goldberg, S. B. ;

Awad, M. M. ;

Garon, E. B. ;

Gettinger, S. ;

Hellmann, M. D. ;

Politi, K. .

ANNALS OF ONCOLOGY, 2019, 30 (08) :1311-1320

[10] Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors [J].

Heinhuis, K. M. ;

Ros, W. ;

Kok, M. ;

Steeghs, N. ;

Beijnen, J. H. ;

Schellens, J. H. M. .

ANNALS OF ONCOLOGY, 2019, 30 (02) :219-235

← 1 2 →